Table 3

Unadjusted change from baseline health status scores after AMI, stratified by diabetes status

Health status outcomesWithout diabetes
(n=2008, 57.4% of 3501 participants) (a)
P value* changes in (b) vs (a)Newly diagnosed diabetes
(n=508, 14.5% of 3501 participants) (b)
P value† changes in
(b) vs (c)
Established diabetes
(n=985, 28.1% of 3501 participants) Mean (SD) (c)
Baseline mean (SD)Follow-Up mean (SD)Change from baseline mean (95% CI)Baseline mean (SD)Follow-Up mean (SD)Change from baseline mean (95% CI)Baseline mean (SD)Follow-up mean (SD)Change from baseline mean (95% CI)
1-month follow-up
 SAQ-Angina Frequency85.84 (18.94)89.51 (17.27)4.03 (2.89 to 5.18)0.68585.50 (18.12)89.36 (17.89)3.54 (1.39 to 5.69)0.00579.33 (23.73)87.39 (18.53)8.56 (6.73 to 10.39)
 SAQ-Physical Limitations84.56 (22.93)89.90 (19.09)7.08 (5.82 to 8.34)0.29482.51 (24.96)90.89 (18.54)8.67 (5.98 to 11.36)0.00173.77 (28.72)88.91 (20.94)16.05 (13.95 to 18.16)
 SAQ-Quality of Life57.48 (22.84)67.94 (24.57)11.62 (10.20 to 13.04)0.72959.96 (25.29)71.27 (24.41)11.10 (8.42 to 13.78)0.11852.94 (25.25)66.39 (26.40)13.81 (11.75 to 15.88)
 SF-12 Mental Functioning46.36 (12.37)49.61 (10.85)2.77 (2.13 to 3.42)0.00145.84 (12.14)51.54 (9.50)5.65 (4.43 to 6.87)0.37043.21 (12.81)48.61 (11.21)4.95 (4.04 to 5.87)
 SF-12 Physical Functioning45.84 (11.65)43.51 (11.28)−1.98 (-2.61 to -1.35)0.61644.24 (11.82)42.06 (11.78)−2.31 (-3.47 to -1.16)0.14839.71 (12.06)38.10 (11.75)−1.28 (−2.11 to -0.45)
 EQ-5D-VAS66.34 (20.62)71.75 (20.09)16.82 (15.99 to 17.66)0.88867.06 (21.11)72.04 (19.90)16.94 (15.48 to 18.41)0.07858.49 (22.27)67.37 (22.40)18.64 (17.49 to 19.79)
12-month follow-up
 SAQ-Angina Frequency85.84 (18.94)92.06 (16.03)6.66 (5.51 to 7.82)0.62385.50 (18.12)92.56 (14.37)7.26 (5.22 to 9.30)0.11179.33 (23.73)89.21 (19.12)9.60 (7.56 to 11.63)
 SAQ-Physical Limitations84.56 (22.93)91.87 (17.98)8.29 (6.97 to 9.61)0.12782.51 (24.96)93.31 (16.03)10.59 (7.94 to 13.23)0.00573.77 (28.72)89.79 (21.62)15.62 (13.31 to 17.93)
 SAQ-Quality of Life57.48 (22.84)72.23 (22.51)15.35 (13.90 to 16.79)0.80159.96 (25.29)75.74 (22.01)15.76 (12.91 to 18.61)0.36752.94 (25.25)70.32 (24.88)17.43 (15.18 to 19.69)
 SF-12 Mental Functioning46.36 (12.37)50.61 (10.80)3.88 (3.19 to 4.57)0.09645.84 (12.14)51.27 (9.70)5.09 (3.79 to 6.40)0.97943.21 (12.81)48.81 (11.79)5.12 (4.03 to 6.20)
 SF-12 Physical Functioning45.84 (11.65)46.14 (11.55)0.66 (0.00 to 1.32)0.58144.24 (11.82)45.03 (12.21)0.23 (-1.12 to 1.58)0.53239.71 (12.06)40.61 (12.83)0.76 (−0.19 to 1.70)
 EQ-5D-VAS66.34 (20.62)73.61 (20.22)8.09 (6.80 to 9.37)0.96567.06 (21.11)75.73 (18.34)8.03 (5.65 to 10.40)0.20258.49 (22.27)68.55 (22.87)10.05 (8.03 to 12.06)
  • P-value numbers in bold denote statistical significance at the p<0.05 level.

  • *Unadjusted p values were testing for differences in mean changes of health status scores between patients with newly diagnosed and without diabetes.

  • †Unadjusted p values were testing for differences in mean changes of health status scores between patients with newly diagnosed and established diabetes.

  • EQ-5D-VAS, Euro-Quality of Visual Analogue Scale; SAQ, Seattle Angina Questionnaire; SF-12, 12 Item Short Form Survey.